Want to see TSE:RHEL full AI Analyst Report?
Red Light Holland (RHEL) AI Stock Analysis
Red Light Holland
(CNQX:RHEL)
The score is primarily held back by weak financial performance, including persistent losses, ongoing cash burn, and declining equity despite low debt. Technicals also weigh on the outlook with the stock trading below key moving averages and only mixed momentum signals. Valuation is somewhat offsetting but limited, as the negative P/E reflects unprofitable operations and no dividend yield is available.
Red Light Holland (RHEL) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 8.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 222.54K
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.71
- Revenue Growth
- -36.49%
- EPS Growth
- -64.44%
- Country
- Canada
- Employees
- 104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Red Light Holland Business Overview & Revenue Model
Company Description
Based in Toronto, Ontario, Red Light Holland Corp. is primarily involved in the cultivation, production, and retail of recreational magic truffles for the Dutch market. Beyond its own cultivated offerings, the company also engages in the sourcing, di...
Red Light Holland Financial Statement Overview
Summary
Despite meaningful revenue scaling versus early years and low leverage, profitability and cash generation remain weak. The company continues to post large operating and net losses relative to revenue, recurring negative operating/free cash flow, and shrinking equity, indicating ongoing capital consumption.
Income Statement
23NegativeBalance Sheet
56NeutralCash Flow
27Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.20M | 4.20M | 4.94M | 4.75M | 2.33M | 110.96K |
| Gross Profit | 1.33M | 1.23M | 1.91M | 2.02M | 617.68K | 19.35K |
| EBITDA | -4.19M | -4.07M | -3.35M | -6.58M | -8.55M | -4.61M |
| Net Income | -6.10M | -6.10M | -4.04M | -7.63M | -14.37M | -1.64M |
Balance Sheet | ||||||
| Total Assets | 14.57M | 14.57M | 21.22M | 24.08M | 32.94M | 36.30M |
| Cash, Cash Equivalents and Short-Term Investments | 9.05M | 9.05M | 12.27M | 14.17M | 26.62M | 32.78M |
| Total Debt | 286.64K | 286.64K | 2.18M | 1.72M | 1.50M | 866.50K |
| Total Liabilities | 3.35M | 3.35M | 3.87M | 3.82M | 3.78M | 2.24M |
| Stockholders Equity | 11.97M | 11.97M | 17.35M | 20.07M | 28.48M | 34.06M |
Cash Flow | ||||||
| Free Cash Flow | -2.56M | -2.56M | -2.01M | -3.92M | -5.28M | -3.63M |
| Operating Cash Flow | -2.42M | -2.42M | -1.48M | -3.23M | -4.88M | -3.36M |
| Investing Cash Flow | -1.23M | -1.23M | -525.40K | -650.43K | -582.74K | -201.55K |
| Financing Cash Flow | -766.03K | -766.03K | 445.17K | -206.95K | 451.76K | 32.78M |
Red Light Holland Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RHEL, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 25.31 is Positive, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RHEL.
Red Light Holland Peers Comparison
Overall Rating
TSE:CURA59Neutral
TSE:CWEB53Neutral- TSE:RHEL46Neutral
TSE:MUSH42Neutral
TSE:RVV42Neutral
TSE:PLTH40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:CURA | 59Neutral | CAD 3.12B | -60.28 | -4.47% | ― | 1.50% | 81.84% |
| TSE:CWEB | 53Neutral | CAD 84.10M | -1.06 | -285.96% | ― | -7.77% | -52.56% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:RHEL | 46Neutral | CAD 12.28M | -2.07 | -41.33% | ― | -36.49% | -64.44% |
| TSE:MUSH | 42Neutral | CAD 5.17M | -500.00 | -2.30% | ― | 52.89% | 98.68% |
| TSE:RVV | 42Neutral | CAD 8.37M | -0.83 | 26.78% | ― | ― | 90.84% |
| TSE:PLTH | 40Underperform | CAD 35.21M | -0.39 | -131.41% | ― | -21.90% | -25.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:RHEL | Red Light Holland Corp | 0.02 | -0.01 | -33.33% | |
| TSE:MUSH | Good Shroom Co Inc | 0.10 | -0.01 | -9.09% | |
| TSE:RVV | Revive Therapeutics | 0.02 | 0.01 | 100.00% | |
| TSE:CWEB | Charlotte's Web Holdings (OTC) | 0.31 | 0.11 | 55.00% | |
| TSE:CURA | Curaleaf Holdings (Otc) | 11.77 | 0.04 | 0.34% | |
| TSE:PLTH | Planet 13 Holdings, Inc. | 0.10 | -0.17 | -61.82% |
Red Light Holland Corporate Events
Rhelion’s Filament Health to Supply Psilocybin Candidate PEX010 for Swedish Social Anxiety Trial
PositiveRhelion Life Sciences, through its subsidiary Filament Health, has signed a supply and licensing agreement with Sweden’s Linköping University to provide its patented botanical psilocybin candidate PEX010 for the PsiloSAD clinical trial in...
Rhelion’s Filament to Supply Psilocybin for Belgium’s First Compassionate Use Program
PositiveRhelion Life Sciences, through its wholly owned subsidiary Filament Health, operates in the legal psychedelic sector, specializing in naturally derived psilocybin drug candidates. Its lead product, the patented botanical psilocybin drug candidate PEX...
Rhelion Reappoints Psychedelic Research Leader as Advisor and Moves to Restructure Debt
PositiveRhelion Life Sciences has reappointed leading psychedelic researcher Dr. Robin Carhart-Harris as Scientific Advisor, extending a relationship that began in June 2025. He will provide scientific and strategic guidance, regularly interface with managem...
Rhelion Subsidiary Filament to Supply Psilocybin for UCSF Trial on Meth Use Disorder in People With HIV
PositiveRhelion Life Sciences’ subsidiary Filament Health has signed a licence and supply agreement with the University of California, San Francisco to provide its botanical psilocybin candidate PEX010 for a Phase 2 trial. The study will evaluate wheth...
Rhelion Unit Ships Psilocybin Candidate for PTSD Trial in Calgary
PositiveRhelion Life Sciences, through its subsidiary Filament Health, has shipped its patented botanical psilocybin candidate PEX010 to the University of Calgary for a Phase 2 clinical trial. The study, known as PsiPTSD, will investigate psilocybin-assisted...
Rhelion’s Filament Unit Boosts Psilocybin Supply for Landmark Italian Depression Trial
PositiveRhelion Life Sciences, via its subsidiary Filament Health, has expanded its supply and licence agreement with the University G. d’Annunzio of Chieti-Pescara for its psilocybin drug candidate PEX010 in the TEMPO clinical trial for treatment-resi...
Rhelion Subsidiary Filament Health Wins New Canadian Patent for Natural Psilocybin
PositiveRhelion Life Sciences, via its wholly owned subsidiary Filament Health, has secured a new Canadian patent covering psychoactive alkaloid extraction and compositions with controlled dephosphorylation for natural psilocybin. The patent strengthens prot...
Rhelion Subsidiary Supplies Psilocybin for Phase 3 Palliative Care Trial
PositiveRhelion Life Sciences’ subsidiary Filament Health has delivered its standardized botanical psilocybin candidate PEX010 to Bruyère Health Research Institute for a Phase 3, multi-site, placebo-controlled clinical trial in palliative care. Th...
Rhelion’s Filament Health inks psilocybin supply deal with Dutch research centre
PositiveRhelion Life Sciences, through its wholly owned subsidiary Filament Health, is advancing naturally derived psilocybin-based therapeutics within the legal psychedelic sector. Filament develops and supplies its patented botanical psilocybin drug candid...
Rhelion’s Filament Health to Supply Psilocybin Candidate PEX010 for USC Mindfulness Trial
PositiveRhelion Life Sciences, via its wholly owned subsidiary Filament Health, operates in the legal psychedelic sector with a focus on developing naturally derived psilocybin therapies. The company leverages Filament’s patented PEX010 drug candidate...
Rhelion Unit Filament Ships Psilocybin Drug to Australia for First-of-Its-Kind FND Trial
PositiveRhelion Life Sciences, via its wholly owned subsidiary Filament Health, has shipped its patented botanical psilocybin drug candidate PEX010 from Canada to Australia. The product will be used at Austin Health in Melbourne in PSI-PHY, an investigator-i...
Rhelion Subsidiary Ships Psilocybin Candidate to Australia for Novel Movement Disorder Trial
PositiveRhelion Life Sciences’ subsidiary Filament Health has exported its patented botanical psilocybin candidate PEX010 from Canada to Australia for the PSI-PHY pilot trial, which will test psilocybin-assisted physiotherapy in adults with refractory...
Rhelion Expands Role in EU Psilocybin Access With New PEX010 Delivery to Germany
PositiveRhelion Life Sciences, via its subsidiary Filament Health, has completed an additional shipment of its patented, GMP-manufactured botanical psilocybin candidate PEX010 to Germany’s Central Institute of Mental Health. The drug is being used in G...
Rhelion Life Sciences Marks Transformational Quarter With Filament Acquisition and Psychedelic Drug Push
PositiveRhelion Life Sciences reported results for the first quarter of fiscal 2027, highlighting a transformational period marked by the closing of its acquisition of Filament Health and the launch of a new life sciences platform. The deal shifts Rhelion...
Rhelion’s Filament Unit Wins New U.S. Patent, Expanding Natural Psilocybin IP Estate
PositiveRhelion Life Sciences, through its subsidiary Filament Health, has strengthened its position in the legal psychedelic drug sector by securing a new United States patent for dephosphorylation-controlled extraction of psychoactive alkaloids. This paten...
Rhelion’s Filament Health Supplies Psilocybin PEX010 for University of Washington Cancer Anxiety Trial
PositiveRhelion Life Sciences, through its subsidiary Filament Health, is strengthening its role in the legal psychedelic therapeutics sector by supplying patented botanical psilocybin to research and compassionate use programs worldwide. Its lead drug candi...
Rhelion’s Filament Health to Harness FDA-Authorized AI Imaging in Psilocybin Alzheimer’s Trial Design
PositiveRhelion Life Sciences’ subsidiary Filament Health has signed a non-binding letter of intent with San Francisco-based Darmiyan to explore integrating Darmiyan’s FDA De Novo authorized BrainSee AI imaging platform into the design of future...
Rhelion Life Sciences Names New CFO as Psychedelic Drug Platform Expands
PositiveRhelion Life Sciences, an Ontario-based psychedelic life sciences company, has reshaped its business around pharmaceutical drug development and regulated supply of naturally derived psychedelic medicines following the acquisition of Filament Health....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026